This text is translated into Russian by google automatic human level neural machine.
EastRussia is not responsible for any mistakes in the translated text. Sorry for the inconvinience.
Please refer to the text in Russian as a source.
Favipiravir received permanent registration in Russia
The drug for the treatment of coronavirus "Favipiravir" has received permanent registration in Russia. Previously, this drug was subject to an accelerated admission procedure.
As the TASSViktor Fisenko, Deputy Minister of Health of the Russian Federation, spoke about obtaining a permanent registration certificate for Favipiravira. He specified that the drugs Remdesivir and Levilimab were also admitted under the accelerated procedure.
Earlier it was reported that first cure for coronavirus - "Avifavir" - was registered in Russia in May 2020. Then, in June, another drug, Areplevir, was registered. After that, in early July, the Ministry of Health also approved the drug Coronavir.
In October, the coronavirus drug was added to the list of essential essential drugs. This is about Favipiravire (trade name - "Coronavir").